Serge Muyldermans started his studies at the ‘Vrije Universiteit Brussel’ and obtained his PhD in 1982 on structural aspects of nucleosomes and chromatin. As a postdoc at the same university he became involved in the early 90-ies in the camel antibody program. In 2003 he was appointed Professor at the Vrije Universiteit Brussel, where he is now heading the camel antibody engineering group in the laboratory of Cellular and Molecular Immunology. The discovery of camel Heavy-chain antibodies and the applications of their unique single variable antigen-binding domain (now referred to as Nanobodies) led to the publication of over 150 articles in peer reviewed international journals, many of which appeared in top journals. In January 2002, he was co-founder of ‘Ablynx’, a spin-off company that generates Nanobodies for therapeutic purposes. Ablynx is currently employing ~300 people and has several Nanobodies in clinical trials.
Abstracts this author is presenting: